Anika Therapeutics Inc. · NASDAQ:ANIK
Anika Therapeutics — Q1 2025 Earnings Presentation
15 slides from Anika Therapeutics's earnings presentation, May 9, 2025
Slide 1: Q1 2025 Earnings Call
Q1 2025 EARNINGS CALL MAY 9, 2025 Anika. Restore Active Living.
Slide 2: Safe Harbor Statements
SAFE HARBOR STATEMENTS Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company’s commercial capabilities, initiatives and production, its product pipeline and
Slide 3: Company Highlights
COMPANY HIGHLIGHTS STRATEGIC FOCUS DRIVING COMMERCIAL GROWTH AND PIPELINE ADVANCEMENT Commercial Update Pipeline Progress Company Transformation • Integrity Implant System • Integrity – Advanced platform • Completed sale of Parcus Medical procedures tracking to more than expansion for foot and ankle
Slide 4: Q1 2025 Financial Highlights
Q1 2025 FINANCIAL HIGHLIGHTS $M, except per share data CONTINUING OPERATIONS 1Q25 Continuing Operations Highlights Q1 Financial Results 2025 VPY • Revenue decreased by 10% to $26.2M driven by Revenue $26.2 (10%) 23% decrease in OEM Revenue due to lower pricing both in transfer units and royalties on
Slide 5: 2025 Guidance: Updated OEM Revenue and Adjusted EBITDA
2025 GUIDANCE: UPDATED OEM REVENUE AND ADJUSTED EBITDA $M 2021 2022 2023 2024 2025 Est 1 2026 Est 1 2027 Est 1 Commercial Revenue • International OA Pain +17% 3-Year CAGR • Regenerative Solutions • Hyalofast (4Q26-2027) +20-30% $47-49.5 +20-30% $32 $36 $42 +12-18% $26 OEM Revenue • US OA Pain though
Slide 6: Strategies to Deliver Shareholder Value
3 STRATEGIES TO DELIVER SHAREHOLDER VALUE Near-Term: Deliver market leading OA Pain Management products and achieve full potential of Integrity (2025) Implant System in high-growth $220M tendon augmentation TAM Mid-Term: Obtain FDA approval and successfully launch Hyalofast® in Anika’s Commercial Ch
Slide 7: @ ANIKA
@ ANIKA
Slide 8: Non-GAAP Reconciliation and Supplemental Data
NON-GAAP RECONCILIATION AND SUPPLEMENTAL DATA 8
Slide 9: Statement of Operations
STATEMENT OF OPERATIONS ‘Anika Therapeutics, Inc. and Subsidiaries Consolidated Statements of Operations (in thousands, except per share data) (unaudited) For the Three Months Ended March 31, ——__25__ 2 Revenue $ 26168 $ 29022 Costof Revenve 187 toot Gross Profit, 14681 18,975 Operating expenses: Re
Slide 10: Balance Sheet
BALANCE SHEET Consolidated Balance Sheets (Onthousands, except per share data) (unaudited) ‘March31, ASSETS 2025, Current assets: CCash and cash equivalents $ s337 ‘Accounts recelvable, net 21,987 overtones, net 21336 Prepaid expenses and other current assets sas Current assets held forsale Total cu
Slide 11: Reconciliation Tables – GAAP Net Loss to Adjusted EBITDA
RECONCILIATION TABLES – GAAP NET LOSS TO ADJUSTED EBITDA 11
Slide 12: Reconciliation Tables – GAAP Net Income to Adjusted Net Income
RECONCILIATION TABLES – GAAP NET INCOME TO ADJUSTED NET INCOME 12
Slide 13: Reconciliation Tables – GAAP EPS to Adjusted EPS
RECONCILIATION TABLES – GAAP EPS TO ADJUSTED EPS 13
Slide 14: Revenue by Channel
REVENUE BY CHANNEL Anika Therapeutics, Inc. and Subsidiaries Revenue by Product Family {in thousands, except percentages) (unaudited) OEM Channel Commercial Channel @ ANIKA For the Three Months Ended March 31, 2025 2024 $ change ‘% change $ 14,909 $ 19450 $ (4541) “23% 11,259 9572 1687 18% $26,168 $
Slide 15: @ ANIKA
@ ANIKA